Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including Biogen (BIIB)/Eisai’s Leqembi and Lilly’s Kisunla on an Analyst/Industry conference call to be held on November 13 at 11 am.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter